West Virginia CTSI awards $360,000 in pilot grants | WVU Healthcare

West Virginia CTSI awards $360,000 in pilot grants | WVU Healthcare.

Figure_of_Oded_path_w_graph_GPSM3KO_TAKE3In a recent basic research program studying molecular determinants of the human and rodent immune systems, the Siderovski lab (in collaboration with colleagues at UNC-Chapel Hill) found that a novel regulator of chemokine receptor signaling, GPSM3, is highly expressed in monocytes – a key inflammatory cell-type that is central to the disease processes of rheumatoid arthritis. Mice deficient in GPSM3 expression were found to have blunted disease in an acute inflammatory arthritis model. Independent, genome-wide association studies have now discovered that two frequent mutations within the human GPSM3 gene are associated with substantial protection from rheumatoid arthritis, as well as other autoimmune diseases, suggesting that GPSM3 may serve as an important regulator in autoimmunity. Therefore, the specific research funded by this WVCTSI Pilot Award is to determine whether there are functional differences in GPSM3 mRNA transcripts and protein expression that correlate with the frequent gene mutations in healthy controls and autoimmune patients with RA.

Advertisements

One thought on “West Virginia CTSI awards $360,000 in pilot grants | WVU Healthcare

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s